CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 475 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $860,000 | -54.2% | 15,918 | -46.9% | 0.08% | -57.1% |
| Q4 2023 | $1,876,000 | +64.3% | 29,962 | +19.1% | 0.18% | +9.5% |
| Q3 2023 | $1,142,000 | -5.4% | 25,160 | +17.0% | 0.17% | +20.0% |
| Q2 2023 | $1,207,000 | +24.2% | 21,500 | 0.0% | 0.14% | +15.7% |
| Q1 2023 | $972,000 | -52.5% | 21,500 | +70.0% | 0.12% | -60.2% |
| Q2 2021 | $2,048,000 | +49.9% | 12,650 | +12.9% | 0.30% | +30.5% |
| Q1 2021 | $1,366,000 | – | 11,209 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |